<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302822</url>
  </required_header>
  <id_info>
    <org_study_id>2005-004722-12</org_study_id>
    <secondary_id>2005-004722-12</secondary_id>
    <nct_id>NCT00302822</nct_id>
  </id_info>
  <brief_title>Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)</brief_title>
  <official_title>Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV infection is diagnosed late in a substantial proportion of patients having an increased
      risk of clinical progression (AIDS, new AIDS-defining event or death). The currently
      recommended antiretroviral therapy has suboptimal activity in this setting and potent
      quadruple-drug therapy has not been sufficiently evaluated. Enfuvirtide may be an appropriate
      candidate as the fourth antiretroviral agent, regarding its activity, its parenteral
      administration avoiding gastrointestinal symptoms that often lead to interruption of
      treatment, the lack of pharmacokinetic interactions and the absence of systemic toxicity.

      The aim of this study is to investigate, in a comparative intensification trial, the
      immunological benefit of adding enfuvirtide for 6 months to a conventional antiretroviral
      therapy in HIV-1 infected and severely immunosuppressed patients, naïve of any antiretroviral
      treatment.

      We postulate that addition of enfuvirtide to a first-line antiretroviral therapy consisting
      in emtricitabine/tenofovir combined with either efavirenz or lopinavir/r may improve
      immunological restoration, measured as the proportion of patients with more than 200 CD4
      cells per mm3 after 24 weeks of antiretroviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, open-label study is to evaluate the immunological efficacy of
      two first-line strategies of antiretroviral therapy:

        1. emtricitabine/tenofovir disoproxil fumarate coformulated plus efavirenz (or lopinavir/r)
           intensified by enfuvirtide during the first 24 weeks of therapy.

        2. emtricitabine/tenofovir disoproxil fumarate coformulated plus efavirenz (or lopinavir/r)

      Patients with lymphocytes T CD4+ cell (CD4)count below 100 per mm3, or CD4 cell count below
      200 per mm3 and past history or presence of AIDS defining event and naïve of any
      antiretroviral therapy will be eligible. This multicenter study will enroll 220 patients
      (n=110 in each arm). The planned duration of the study is 48 weeks from the enrolment of the
      last subject.

      The primary endpoint will be immunological success defined as CD4 cell count above 200 cells
      per mm3 after 24 weeks of initial treatment. The durability of this response will be
      evaluated and patients will be followed for 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological success defined as a CD4 cell count above 200 cells per mm3 after 24 weeks of initial antiretroviral treatment</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological response, clinical progression, tolerance,toxicity, quality of life under therapy, adherence and resistance mutations emerging in case of virological failure.</measure>
    <time_frame>from 0 to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Intensification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lopinavir or efavirenz and emtricitabine/tenofovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enfuvirtide</intervention_name>
    <description>from week 0 to 24</description>
    <arm_group_label>Intensification</arm_group_label>
    <other_name>Fuzeon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine/tenofovir</intervention_name>
    <description>1 pill/day</description>
    <arm_group_label>Intensification</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir or efavirenz</intervention_name>
    <description>investigator choice</description>
    <arm_group_label>Intensification</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Kaletra, Sustiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Antiretroviral naïve HIV-1 infected patients

          -  CD4 cell count below 100 per mm3, or CD4 cell count below 200/mm3 and past history or
             presence of B or C(AIDS defining)event

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnancy; breast feeding

          -  Coinfection with HIV-2 or infection with HIV-1 subtype O

          -  Antiretroviral pretreated patients

          -  Neoplasia disease currently treated with chemotherapy or radiotherapy

          -  Severe liver failure

          -  Treatment with cytokines or HIV vaccine trial

          -  One or more of the following biological abnormalities: hemoglobin below 10 g/dl,
             Neutrophils below 750 per mm3, thrombocytopenia below 50000 per mm3, creatinine
             clearance below 60 ml per min, Liver Function Tests over 3 Upper Limit of Normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique Joly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Bichat Claude Bernard Paris France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève Chêne, MD PHD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM U897 Bordeaux France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses A Hôpital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://aac.asm.org/content/57/2/758</url>
    <description>Publication with principal results of ANRS 130 APOLLO</description>
  </link>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2006</study_first_submitted>
  <study_first_submitted_qc>March 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2006</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infections</keyword>
  <keyword>Fuzeon</keyword>
  <keyword>Truvada</keyword>
  <keyword>AIDS</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Enfuvirtide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

